Pfizer Hosts Annual Meeting Of Shareholders

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 28-cent second-quarter 2015 dividend on the company’s common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015. The second-quarter 2015 cash dividend will be the 306th consecutive quarterly dividend paid by Pfizer.

“Forward-Looking Information That May Affect Future Results”

“In 2014, we returned nearly $12 billion to shareholders through dividends and share repurchases,” said Ian Read, chairman and chief executive officer. “In 2015, we are continuing to take actions to enhance shareholder value, including our dividend increase announced in December 2015 and share repurchase activity, as well as our proposed acquisition of Hospira, which we expect to strengthen our business and accelerate near-term value creation for shareholders.”

Preliminary results from the Annual Meeting of Shareholders held today indicate that the company’s 11 director nominees were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer’s independent registered public accounting firm for the 2015 fiscal year. In addition, shareholders voted in support of the board-sponsored proposal to approve, on an advisory basis, the compensation of the company’s named executive officers.

In other voting, a shareholder proposal was not approved by the shareholders.

The final results are subject to verification by the independent election inspectors. The final results will be reported on a Form 8-K to be filed by Pfizer with the Securities and Exchange Commission in the next few days.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as of April 23, 2015. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information about the Company’s actions to enhance shareholder value, including with respect to dividends and share repurchases and the Company’s proposed acquisition of Hospira, Inc. and their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in the Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Forms 10-Q and 8-K, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com.